1
Infectious Diseases, Mayo clinic, Phoenix, Arizona
2
Infectious Disease, Mayo Clinic, Phoenix, Arizona
10.30491/ijtmgh.2023.406839.1371
Abstract
The field of immune based therapeutics for treatment of common chronic illnesses has exploded leading to significant improvement in the disease processes but a downstream impact on infections. Janus kinase (JAK) inhibitors and Bruton Tyrosine kinase (BTK) inhibitors are becoming more widely used in treatment of chronic inflammatory diseases and chronic leukemias because of simplicity of oral administration. As such, many patients will have improvement in their underlying illnesses and will have greater flexibility to travel. Thus, it is important for travel medicine practitioners to be aware of these agents, their adverse effects and impact on drug interactions and immunizations.
Nagarakanti, S., & Orenstein, R. (2023). Navigating Travel with Novel Oral JAK and BTK Inhibitors: Beyond Biologics. International Journal of Travel Medicine and Global Health, 11(4), 402-405. doi: 10.30491/ijtmgh.2023.406839.1371
MLA
Sandhya Nagarakanti; Robert Orenstein. "Navigating Travel with Novel Oral JAK and BTK Inhibitors: Beyond Biologics". International Journal of Travel Medicine and Global Health, 11, 4, 2023, 402-405. doi: 10.30491/ijtmgh.2023.406839.1371
HARVARD
Nagarakanti, S., Orenstein, R. (2023). 'Navigating Travel with Novel Oral JAK and BTK Inhibitors: Beyond Biologics', International Journal of Travel Medicine and Global Health, 11(4), pp. 402-405. doi: 10.30491/ijtmgh.2023.406839.1371
VANCOUVER
Nagarakanti, S., Orenstein, R. Navigating Travel with Novel Oral JAK and BTK Inhibitors: Beyond Biologics. International Journal of Travel Medicine and Global Health, 2023; 11(4): 402-405. doi: 10.30491/ijtmgh.2023.406839.1371
)
